Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ikena Oncology (IKNA)
NASDAQ:IKNA
Ikena Oncology (IKNA) Stock Price & Analysis
89 Followers
IKNA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.02 - $7.64
Previous Close$1.26
Volume184.62K
Average Volume (3M)431.67K
Market Cap
$60.81M
Enterprise Value-$102.97M
Total Cash (Recent Filing)$175.47M
Total Debt (Recent Filing)$11.69M
Price to Earnings (P/E)-0.8
Beta1.23
Next Earnings
May 09, 2024EPS Estimate
-$0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.63
Shares Outstanding48,258,111
10 Day Avg. Volume245,518
30 Day Avg. Volume431,668
Standard Deviation0.26
R-Squared0.00411
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)0.36
Price to Sales (P/S)6.53
Price to Cash Flow (P/CF)-0.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-11.24
Enterprise Value/Gross Profit-11.24
Enterprise Value/Ebitda2.95
Forecast
1Y Price Target
$9.50Price Target Upside653.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Ikena Oncology News
PremiumCompany Announcements
Ikena Oncology Announces Leadership Change and Strategic ShiftBulls Say, Bears Say
Bulls Say
Clinical TrialsClinical update expected in 2H24 to show a clear divergence between the new/prior formulations of IK-930, indicating increased exposure levels with a favorable PK/PD profile.
Drug DevelopmentIkena's portfolio encompasses some of the most undervalued assets within oncology, with innovative pathways being targeted.
Financial HealthIkena has sufficient cash through 2H26, allowing for a steady flow of updates to reengage investors.
Bears Say
Adverse Drug ReactionsTwo EHE patients experienced Grade 3-4 liver enzyme elevation, one deemed dose limiting.
Clinical Trial ResultsUpon release of the data, IMRX stock fell stemming from a lack of efficacy at the RP2D dose level, bringing into question IMM-1-104’s mechanistic rationale.
Drug Efficacy ConcernsWhile IMM-1-104 was designed to have a short plasma half-life, the strategy's improvement on safety seems thus far to come at the cost of efficacy.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IKNA FAQ
What was Ikena Oncology’s price range in the past 12 months?
Ikena Oncology lowest stock price was $1.02 and its highest was $7.64 in the past 12 months.
What is Ikena Oncology’s market cap?
Currently, no data Available
When is Ikena Oncology’s upcoming earnings report date?
Ikena Oncology’s upcoming earnings report date is May 09, 2024 which is in 19 days.
How were Ikena Oncology’s earnings last quarter?
Ikena Oncology released its earnings results on Mar 12, 2024. The company reported -$0.41 earnings per share for the quarter, beating the consensus estimate of -$0.416 by $0.006.
Is Ikena Oncology overvalued?
According to Wall Street analysts Ikena Oncology’s price is currently Undervalued.
Does Ikena Oncology pay dividends?
Ikena Oncology does not currently pay dividends.
What is Ikena Oncology’s EPS estimate?
Ikena Oncology’s EPS estimate is -$0.4.
How many shares outstanding does Ikena Oncology have?
Ikena Oncology has 48,258,110 shares outstanding.
What happened to Ikena Oncology’s price movement after its last earnings report?
Ikena Oncology reported an EPS of -$0.41 in its last earnings report, beating expectations of -$0.416. Following the earnings report the stock price went down -4.795%.
Which hedge fund is a major shareholder of Ikena Oncology?
Among the largest hedge funds holding Ikena Oncology’s share is Omega Fund Management, LLC. It holds Ikena Oncology’s shares valued at 4M.
---
Ikena Oncology Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.50 (653.97% Upside)
$9.50 (653.97% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▼ 3.0%
Last 30 Days ▲ 25.5%
Last 30 Days ▲ 25.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-75.20%
12-Months-Change
Fundamentals
Return on Equity
-43.04%
Trailing 12-Months
Asset Growth
11.51%
Trailing 12-Months
Company Description
Ikena Oncology
Ikena Oncology Inc is an oncology company. It is focused on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. The company is advancing five clinical, preclinical and discovery programs: IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; IK-412, a kynurenine-degrading enzyme Kynase; discovery-stage molecules targeting the Hippo signaling pathway; and a discovery-stage program against an undisclosed target.
---
IKNA Stock 12 Months Forecast
Average Price Target
$9.50
▲(653.97% Upside)
Technical Analysis
Best Analysts Covering IKNA
1 Year
1 Year Success Rate
2/7 ratings generated profit
1 Year Average Return
-22.74%
reiterated a buy rating 11 months ago
Copying Judah Frommer's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -22.74% per trade.
---